Datadog Inc (NASDAQ: DDOG) is rallying this morning after the cloud-based observability firm posted its fourth-quarter report that, on the surface, appeared to Datadog Inc (NASDAQ: DDOG) is rallying this morning after the cloud-based observability firm posted its fourth-quarter report that, on the surface, appeared to

Datadog Q4 earnings: sufficient to justify a 230x earnings multiple?

2026/02/11 02:57
3 min read

Datadog Inc (NASDAQ: DDOG) is rallying this morning after the cloud-based observability firm posted its fourth-quarter report that, on the surface, appeared to be a clean beat.

The company reported $953 million in revenue on 59 cents a share of adjusted earnings for its Q4, both handily above Street estimates.  

Datadog Q4 earnings: sufficient to justify a 230x earnings multiple?

However, one could argue that a simple headline beat is no longer enough to justify DDOG shares’ multiple, which sits at an egregiously stretched 230x forward at the time of writing.

A deeper dive into the numbers suggests Datadog’s valuation may have decoupled from the firm’s fundamental reality.

2026 guidance could hurt Datadog stock

Investors are treating Datadog stock as an artificial intelligence (AI) beneficiary, which is why it’s trading at such a premium valuation.

However, if DDOG were optimally capturing the AI tailwinds, you’d expect to see its growth curve accelerating.

Instead, the management’s full-year guidance suggests it’s a maturing business facing gravity.

Datadog sees its revenue falling between $4.06 billion and $4.10 billion this year, representing a deceleration to roughly 19% growth on a year-over-year basis.

For a company trading at a triple-digit multiple, a “barely in line” outlook is far from encouraging.

In the software-as-a-service (SaaS) market, the rule of thumb is: the higher the multiple, the higher should be the “growth gap”.

But in DDOG’s case, executives’ guidance for sub-20% growth is a signal that the company’s core observability market may be saturating.

If the AI revolution were the massive catalyst the bulls claim it to be, Datadog’s outlook would be moving toward 30% or 40%, not drifting toward the teens.

Technicals warrant caution in playing DDOG shares

Beyond valuation, several structural risks are beginning to mount as well. A huge chunk of Datadog’s artificial intelligence revenue is concentrated in a few massive accounts – most notably OpenAI.

But recent reports suggest OpenAI and other LLM giants are increasingly moving toward building in-house observability tools to save on the “Datadog tax”.

Sure, DDOG now has over 4,300 customers spending more than $100,000 annually, demonstrating the company is effectively moving up-market into big enterprise deals.

However, the OpenAI situation is a “whale” risk that 4,300 smaller fish can’t easily replace.

Additionally, Datadog shares’ technicals aren’t particularly exciting either.

Despite a post-earnings rally, the Nasdaq-listed firm remains decisively below its key moving averages (50-day, 100-day, 200-day), reinforcing that bears are firmly in control.

These technical and fundamental headwinds are making options traders recommend “caution” as well.

According to Barchart, the lower price on contracts expiring mid-June sits at $103 currently, indicating DDOG stock could tumble about 20% over the next four months.   

All in all, with competitive pressure mounting from the likes of Dynatrace and New Relic, which are undercutting on price, Datadog’s “best-in-breed” is under siege in 2026.

The post-earnings rally may look like a breakout, but for a stock this egregiously overvalued, it may be an opportunity to take profit, not initiate a new position.

The post Datadog Q4 earnings: sufficient to justify a 230x earnings multiple? appeared first on Invezz

Market Opportunity
4 Logo
4 Price(4)
$0.009488
$0.009488$0.009488
-4.13%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Silver Price Doesn’t Look Real – And This Video Explains Why

The Silver Price Doesn’t Look Real – And This Video Explains Why

The Silver (XAG) price has been acting strange lately. Just when it looked like the market was settling down, a new argument started spreading fast: silver might
Share
Captainaltcoin2026/02/11 04:00
Will XRP Price Increase In September 2025?

Will XRP Price Increase In September 2025?

Ripple XRP is a cryptocurrency that primarily focuses on building a decentralised payments network to facilitate low-cost and cross-border transactions. It’s a native digital currency of the Ripple network, which works as a blockchain called the XRP Ledger (XRPL). It utilised a shared, distributed ledger to track account balances and transactions. What Do XRP Charts Reveal? […]
Share
Tronweekly2025/09/18 00:00
Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves

The post Health Insurers To Cover Covid Vaccines Despite RFK, Jr. Moves appeared on BitcoinEthereumNews.com. The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee, America’s Health Insurance Plans said Wednesday, Sept. 17, 2025. In this photo is a free flu and Covid-19 vaccine shots available sign, CVS, Queens, New York. (Photo by: Lindsey Nicholson/Universal Images Group via Getty Images) UCG/Universal Images Group via Getty Images The nation’s biggest health insurance companies will continue to cover vaccinations – including those against Covid-19 and seasonal flu – previously recommended by a federal advisory committee. The announcement by America’s Health Insurance Plans (AHIP), which includes CVS Health’s Aetna, Humana, Cigna, Centene and an array of Blue Cross and Blue Shield plans as members, comes ahead of the first meeting of the reconstituted Advisory Committee on Immunization Practices, which now has new members chosen by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine critic. “Health plans are committed to maintaining and ensuring affordable access to vaccines,” AHIP said in a statement Wednesday. “Health plan coverage decisions for immunizations are grounded in each plan’s ongoing, rigorous review of scientific and clinical evidence, and continual evaluation of multiple sources of data.” The move by AHIP is good news for millions of Americans at a time of year when they flock to drugstores, pharmacies, physician’s offices and outpatient clinics to get their seasonal flu and Covid shots. Kennedy’s changes to U.S. vaccine policy have created confusion across the country over whether certain vaccines long covered by insurance would continue to be. AHIP has now provided some clarity for millions of Americans. “Health plans will continue to cover all ACIP-recommended immunizations that were recommended as of September 1, 2025, including updated formulations of the COVID-19 and influenza vaccines, with no cost-sharing…
Share
BitcoinEthereumNews2025/09/18 03:11